Sunday, July 6, 2025 7/6/2025

CLINICAL AND SOCIAL IMPLICATIONS OF COST SHARING FOR CANCER DRUGS

Award Number: K07CA136995
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 09/26/2008
PERIOD OF PERFORMANCE END DATE: 08/31/2013

Group Awards By:

View Award Description

CLINICAL AND SOCIAL IMPLICATIONS OF COST SHARING FOR CANCER DRUGS - DESCRIPTION (provided by applicant): Dr. Yu-Ning Wong, a Medical Oncologist at Fox Chase Cancer Center is dedicated to a career in cancer health services research. Her goal is to develop a multidisciplinary research program to understand the impact of insurance design on cancer drug utilization and clinical outcomes. This Career Development Award will provide the means to take two important steps towards accomplishing this goal. First, it will allow for additional intensive mentored education and training in public policy research, health economics, and advanced statistical methods that will augment the candidate's previous rigorous training in epidemiology, biostatistics, and clinical medicine. Second, it will support the development of an original clinical research program using rigorous epidemiologic, econometric and survey methods to examine the impact of prescription drug insurance coverage on cancer outcomes. As new costly cancer drugs are introduced, patients with both public and private insurance are facing higher out- of-pocket costs. Cost sharing between insurers and patients (though co-payments and deductibles) has been traditionally used to control costs based on an expectation that unnecessary health care utilization will be reduced. However this expectation may result in worse socioeconomic disparities in care since some patients may be unable to afford highly effective cancer treatments. The candidate proposes three complementary studies to address the important, unanswered questions about the impact of cost sharing on cancer outcomes. Project A is a conjoint analysis-based survey to measure how patients make decisions among treatments of varying efficacy, toxicity and cost. Project B uses the results from Project A in a decision analysis model to measure the sensitivity of clinical outcomes to price and patient preferences. This will also allow us to determine if is possible to improve clinical outcomes by using low cost sharing to increase adherence to high value treatments. Project C is a natural experiment using insurance claims to measure the effect of insurance design and sociodemographic factors on the receipt of a new, expensive anti-nausea medication and subsequent outcomes. This research program will triangulate on the nexus of issues central to the understanding of cost sharing on cancer drug utilization and clinical outcomes and form the foundation for the candidate's transition to an independent investigator in cancer health services research. This project will have broad implications for the financing of high cost medical interventions because it will help policy makers, insurers and physicians understand how current models of cost sharing may contribute to socioeconomic disparities in cancer care. Our results may suggest consideration of a novel benefit design that encourages patients to make decisions based on relative value, rather than cost alone.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2012 ( Subtotal = $144,018 )
2012	2012	FOX CHASE CANCER CENTER	7701 BURHOLME AVENUE	PHILADELPHIA	PA	19111	PHILADELPHIA	USA	Cancer Research Manpower	001	5	8/3/2012	NON-COMPETING CONTINUATION	$144,018
2012	2009	FOX CHASE CANCER CENTER	7701 BURHOLME AVE	PHILADELPHIA	PA	19111	PHILADELPHIA	USA	Trans-NIH Recovery Act Research Support	000	2	10/17/2011	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $144,018

Issue Date FY: 2011 ( Subtotal = $144,018 )
2011	2011	FOX CHASE CANCER CENTER	7701 BURHOLME AVENUE	PHILADELPHIA	PA	19111	PHILADELPHIA	USA	Cancer Research Manpower	000	4	7/19/2011	NON-COMPETING CONTINUATION	$144,018
														Subtotal = $144,018

Issue Date FY: 2010 ( Subtotal = $143,678 )
2010	2010	FOX CHASE CANCER CENTER	7701 BURHOLME AVENUE	PHILADELPHIA	PA	19111	PHILADELPHIA	USA	Cancer Research Manpower	000	3	9/17/2010	NON-COMPETING CONTINUATION	$143,678
														Subtotal = $143,678

Issue Date FY: 2009 ( Subtotal = $251,359 )
2009	2009	FOX CHASE CANCER CENTER	333 Cottman Ave	Philadelphia	PA	19111	PHILADELPHIA	USA	Cancer Research Manpower	001	2	8/27/2009	NON-COMPETING CONTINUATION	$143,359
2009	2009	FOX CHASE CANCER CENTER	333 Cottman Ave	Philadelphia	PA	19111	PHILADELPHIA	USA	Trans-NIH Recovery Act Research Support	002	2	9/15/2009	SUPPLEMENT FOR EXPANSION	$108,000
2009	2008	FOX CHASE CANCER CENTER	7701 BURHOLME AVE	PHILADELPHIA	PA	19111	PHILADELPHIA	USA	Cancer Research Manpower	000	1	10/29/2008	NEW	$0
														Subtotal = $251,359

Issue Date FY: 2008 ( Subtotal = $143,378 )
2008	2008	FOX CHASE CANCER CENTER	7701 BURHOLME AVE	PHILADELPHIA	PA	19111	PHILADELPHIA	USA	Cancer Research Manpower	000	1	9/26/2008	NEW	$143,378
														Subtotal = $143,378

Grand Total All Awards = $826,451

Top

All Categories

About

Search

Reports

Data Submission

Award Information

CLINICAL AND SOCIAL IMPLICATIONS OF COST SHARING FOR CANCER DRUGS

Award Number: K07CA136995

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 09/26/2008

PERIOD OF PERFORMANCE END DATE: 08/31/2013

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer